UniQure outlines next steps for Huntington's program as FDA recommends Phase III sham-controlled trial
Source: SeekingAlpha
2026-03-02 16:28:38 ET
More on uniQure
- uniQure N.V. (QURE) Q4 2025 Earnings Call Transcript
- uniQure: Shares Tumble On Fresh FDA Controversy - What Investors Should Know
- uniQure: Now What?
- uniQure falls after FDA commissioner’s comments on rare disease therapy
- uniQure gains as FDA sets up meeting on gene therapy
Read the full article on Seeking Alpha
For further details see:
UniQure outlines next steps for Huntington’s program as FDA recommends Phase III sham-controlled trial
uniQure N.V.
NASDAQ: QURE
QURE Trading
31.2% G/L:
$17.135 Last:
9,041,059 Volume:
$18.015 Open:
QURE Latest News
QURE Stock Data
$1,555,111,367
59,307,892
N/A
61
N/A
Biotechnology & Life Sciences
Healthcare
NL
Amsterdam
